DIMERx develops first-in-class dimer compounds targeting chronic conditions of national healthcare significance. The company focuses on creating novel therapeutic modalities derived from its proprietary dimer technology platform. This work is supported by recognition as a NIDA/NIH HEAL Initiative Awardee.
Funding
$13.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current opioid analgesics carry a high risk of addiction and abuse, leading to significant societal costs and patient harm. Traditional pain management strategies often fail to adequately address chronic pain, leaving patients with limited safe and effective treatment options. There is a need for non-addictive pain relief alternatives that can improve patient outcomes without the dangers associated with conventional opioids.
Solution
DIMERx is developing a novel class of non-addictive oral opioid analgesics using a proprietary covalent dimerization platform. This technology creates dimer drug candidates designed to maximize therapeutic potential while minimizing negative implications, specifically targeting chronic pain. The lead candidate, DMX-101, is a Phase 2-ready non-addictive opioid intended to treat chronic pain without the risks associated with traditional opioids by exclusively targeting peripheral pain receptors. DIMERx is also exploring applications of its dimer technology in rare diseases and proprietary medical food domains.
Target Audience
The primary target audience includes individuals suffering from chronic pain, as well as physicians and healthcare providers seeking safer and more effective pain management solutions.
Features
- Proprietary covalent dimerization platform for creating novel drug candidates
- DMX-101: A Phase 2-ready non-addictive opioid dimer for chronic pain
- Designed to exclusively target peripheral pain receptors, reducing central nervous system side effects and addiction potential
- Oral formulation for convenient administration
- Potential applications in rare diseases and proprietary medical foods